31 results
8-K
VIR
Vir Biotechnology Inc
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
are designed to optimize the Company’s cost structure by reducing the size of its workforce and the number of sites it operates in. The Company … of its innate immunity small molecule group initiated in the third quarter of 2023, will represent approximately 12% of the workforce or 75 positions
DRS/A
EX-10.20
rwh78 cm0izxbpcao
7 Aug 19
Draft registration statement (amended)
12:00am
S-1
EX-10.20
cvpz8vlc 8milwk7ewl
3 Sep 19
IPO registration
4:40pm